Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 351 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs... October 16, 2025 Cancer Control in American Indian and Alaska Native Populations: A Conversation... April 25, 2018 Blood Test Accurately Detects Early-Stage Pancreatic Cancer May 10, 2024 Load more HOT NEWS FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer Veteran and His Loyal Dog Pass Away Within Hours Of Each... What Happens If More People Get Screened for Cancer?
